PMID: 6168823May 1, 1981Paper

Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction

Journal of Cardiovascular Pharmacology
J D HorowitzW J Louis

Abstract

The antiarrhythmic effects of intravenously administered lignocaine and mexiletine were compared over a period of 48 hr in a randomized trial on 24 patients who developed ventricular tachyarrhythmias within 48 hr of the onset of acute myocardial infarction. Mexiletine was given as an initial bolus of 200 mg, followed by an infusion of 1 mg/min reduced to 0.5 mg/min after 1 hr. Lignocaine was given as a bolus of 100 mg, followed by an infusion of 3 mg/min reduced to 2 mg/min after 1 hr. Plasma levels of mexiletine, lignocaine, and monoethylglycinexylidide were monitored. The frequency of "complex" ventricular tachyarrhythmias was significantly lower in the mexiletine-treated group. This group of patients also had significantly fewer ventricular extrasystoles than those receiving lignocaine, the difference being most marked during the second 24 hr of treatment. Too few episodes of ventricular fibrillation occurred for statistical comment. The greater efficacy of mexiletine was not associated with increased drug toxicity.

Citations

May 1, 1990·Clinical Cardiology·A S ManolisN A Estes
Jan 1, 1985·Molecular Aspects of Medicine·J H BottingM J Walker
May 1, 1984·American Heart Journal·R G Shanks
Aug 22, 2015·The Cochrane Database of Systematic Reviews·Arturo J Martí-CarvajalShrikant Bangdiwala
Oct 1, 1995·Journal of Cardiovascular Electrophysiology·R A FilartP R Kowey
Jan 1, 1984·British Journal of Clinical Pharmacology·P A Poole-Wilson
Jan 1, 1986·Pharmacotherapy·P E Fenster, K A Comess
Apr 1, 1986·Drug Intelligence & Clinical Pharmacy·B J Schrader, J L Bauman
Jul 5, 1990·Klinische Wochenschrift·J NitschB Lüderitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

© 2021 Meta ULC. All rights reserved